Full View

Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications

HJL Heerspink, BA Perkins, DH Fitchett, M Husain… - Circulation, 2016 - Am Heart Assoc
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
被引用次数：1270 相关文章

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

HJL Heerspink, BA Perkins, DH Fitchett, M Husain… - …, 2016 - ingentaconnect.com
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

HJL Heerspink, BA Perkins, DH Fitchett, M Husain… - Circulation, 2016 - cir.nii.ac.jp
< jats: p> Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin,
dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies …

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

HJ Heerspink, BA Perkins, DH Fitchett, M Husain… - Circulation, 2016 - europepmc.org
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

HJL Heerspink, BA Perkins, DH Fitchett… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

HJL Heerspink, BA Perkins, DH Fitchett, M Husain… - Circulation, 2016 - research.rug.nl
Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin,
dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies …